Kamran Aryana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8331850/publications.pdf

Version: 2024-02-01

1040056 996975 30 234 9 15 citations h-index g-index papers 30 30 30 308 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with 177Lu-PSMA-617: A single center study. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, 41, 239-246.	0.2	2
2	Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to $lu177\ DOTA$ -TATE treatment. Archives of Endocrinology and Metabolism, 2022, , .	0.6	2
3	Bone scan with technetium 99m-methyl diphosphonate, the missing link in the initial staging of muscle-invasive bladder carcinoma. Nuclear Medicine Communications, 2022, Publish Ahead of Print, .	1.1	O
4	Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?. Contrast Media and Molecular Imaging, 2022, 2022, 1-9.	0.8	18
5	Peptide Receptor Radionuclide Therapy in Radioiodine-Refractory Thyroid Cancer. A Case Report of Significant Response to 177Lu-Dotatate Treatment. World Journal of Nuclear Medicine, 2022, , .	0.5	O
6	Somatostatin receptor imaging and therapy in differentiated thyroid cancer: a ray of hope or the flash before total darkness?. Clinical and Translational Imaging, 2021, 9, 275-276.	2.1	1
7	Incidental finding of a dermoid cyst in a whole-body iodine scan: importance of using [131I]SPECT/CT in the differentiated thyroid carcinoma. Nuclear Medicine Review, 2021, 24, 106-107.	0.5	4
8	Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [18F]F-FDG in Oncology: A Systematic Review. International Journal of Molecular Sciences, 2021, 22, 11192.	4.1	30
9	Whole-Body 177Luâ€"Prostate-Specific Membrane Antigen Scan Pattern With Excess Free 177Lu-Chloride in a Metastatic Castration-Resistant Prostate Cancer Patient. Clinical Nuclear Medicine, 2020, 45,	1.3	O
	805-807.		
10	Medical Event. Clinical Nuclear Medicine, 2020, 45, 439-441.	1.3	1
10		1.3 2.2	3
	Medical Event. Clinical Nuclear Medicine, 2020, 45, 439-441. Fact Checking on ¹⁷⁷ Lu Prostate-Specific Membrane Antigen Nephrotoxicity. American		
11	Medical Event. Clinical Nuclear Medicine, 2020, 45, 439-441. Fact Checking on ¹⁷⁷ Lu Prostate-Specific Membrane Antigen Nephrotoxicity. American Journal of Roentgenology, 2020, 215, W2-W2. 99m Tc-Octreotide-Avid Brain Mass In A Patient With Poorly Differentiated Papillary Thyroid	2.2	3
11	Medical Event. Clinical Nuclear Medicine, 2020, 45, 439-441. Fact Checking on ⟨sup⟩177⟨/sup⟩Lu Prostate-Specific Membrane Antigen Nephrotoxicity. American Journal of Roentgenology, 2020, 215, W2-W2. 99m Tc-Octreotide-Avid Brain Mass In A Patient With Poorly Differentiated Papillary Thyroid Carcinoma, Hope In Despair. Nuclear Medicine Review, 2020, 23, 49-50. Application of 99mTc-UBI 29–41 scintigraphy in knee periprosthetic infection diagnosis. Nuklearmedizin	2.2	3 O
11 12 13	Medical Event. Clinical Nuclear Medicine, 2020, 45, 439-441. Fact Checking on ⟨sup⟩177⟨/sup⟩Lu Prostate-Specific Membrane Antigen Nephrotoxicity. American Journal of Roentgenology, 2020, 215, W2-W2. 99m Tc-Octreotide-Avid Brain Mass In A Patient With Poorly Differentiated Papillary Thyroid Carcinoma, Hope In Despair. Nuclear Medicine Review, 2020, 23, 49-50. i>¿Application of 99mTc-UBI 29–41 scintigraphy in knee periprosthetic infection diagnosis. Nuklearmedizin - NuclearMedicine, 2019, 58, 301-308. Favorable Response After Only One Cycle of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Metastatic Merkel Cell Carcinoma. Clinical Nuclear Medicine, 2019,	2.2 0.5 0.7	3 0 1
11 12 13	Medical Event. Clinical Nuclear Medicine, 2020, 45, 439-441. Fact Checking on ⟨sup⟩177⟨ sup⟩Lu Prostate-Specific Membrane Antigen Nephrotoxicity. American Journal of Roentgenology, 2020, 215, W2-W2. 99m Tc-Octreotide-Avid Brain Mass In A Patient With Poorly Differentiated Papillary Thyroid Carcinoma, Hope In Despair. Nuclear Medicine Review, 2020, 23, 49-50. Application of 99mTc-UBI 29–41 scintigraphy in knee periprosthetic infection diagnosis. Nuklearmedizin - Nuclear Medicine, 2019, 58, 301-308. Favorable Response After Only One Cycle of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Metastatic Merkel Cell Carcinoma. Clinical Nuclear Medicine, 2019, 44, 650-652.	2.2 0.5 0.7	3 0 1 9
11 12 13 14	Medical Event. Clinical Nuclear Medicine, 2020, 45, 439-441. Fact Checking on ¹⁷⁷ Lu Prostate-Specific Membrane Antigen Nephrotoxicity. American Journal of Roentgenology, 2020, 215, W2-W2. 99m Tc-Octreotide-Avid Brain Mass In A Patient With Poorly Differentiated Papillary Thyroid Carcinoma, Hope In Despair. Nuclear Medicine Review, 2020, 23, 49-50. i»;Application of 99mTc-UBI 29–41 scintigraphy in knee periprosthetic infection diagnosis. Nuklearmedizin - NuclearMedicine, 2019, 58, 301-308. Favorable Response After Only One Cycle of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Metastatic Merkel Cell Carcinoma. Clinical Nuclear Medicine, 2019, 44, 650-652. 177Lu–Prostate-Specific Membrane Antigen Super Scan and Good Response Even After 1 Cycle of Radioligand Therapy. Clinical Nuclear Medicine, 2018, 43, 273-275. Diagnostic Value of 99m Tc-Labeled-Ubiquicidin 29-41 (99m Tc-UBI) Scan in the Diagnosis of Vertebral	2.2 0.5 0.7 1.3	3 0 1 9

#	Article	IF	CITATIONS
19	Nano Liposomes Labeled with (99m)Tc-HMPAO, a Novel Agent for Blood Pool Imaging. Iranian Journal of Pharmaceutical Research, 2015, 14, 981-8.	0.5	6
20	Diagnostic value of 99mTc-bombesin scintigraphy for differentiation of malignant from benign breast lesions. Nuclear Medicine Communications, 2014, 35, 620-625.	1.1	19
21	The Role of Octreotate Scan in Discrimination of Solitary Pulmonary Nodule. World Journal of Nuclear Medicine, 2014, 13, 46.	0.5	1
22	Association of Helicobacter pylori infection with the Lewis and ABO blood groups in dyspeptic patients. Nigerian Medical Journal, 2013, 54, 196.	0.6	14
23	Botulinum toxin for prevention of delayed gastric emptying after esophagectomy. Asian Cardiovascular and Thoracic Annals, 2013, 21, 689-692.	0.5	23
24	Treatment efficacy of (153)Sm-EDTMP for painful bone metastasis. Asia Oceania Journal of Nuclear Medicine and Biology, 2013, 1, 27-31.	0.1	14
25	Efficacy of high-energy collimator for sentinel node lymphoscintigraphy of early breast cancer patients. Radiology and Oncology, 2012, 46, 75-80.	1.7	6
26	99mTc-labeled ubiquicidin scintigraphy. Nuklearmedizin - NuclearMedicine, 2012, 51, 133-139.	0.7	23
27	Factors influencing the time of sentinel node visualization in breast cancer patients using intradermal injection of the radiotracer. American Journal of Surgery, 2011, 202, 199-202.	1.8	35
28	Systemic Absorption of Tc-99m-Pertechnetate during Dacryoscintigraphy: A Note of Caution. Orbit, 2010, 29, 269-270.	0.8	6
29	The efficacy of Tc-99m sestamibi for sentinel node mapping in breast carcinomas: comparison with Tc-99m antimony sulphide colloid. Nuclear Medicine Review, 2010, 13, 1-4.	0.5	4
30	99mTc-PSMA Left Behind: a Call for Collaboration. Nuclear Medicine and Molecular Imaging, 0, , .	1.0	2